Baidu
map

Crit Care Med:增加蛋白质和能量摄入对危重症患者死亡率的影响:一项多中心、国际性观察研究

2017-06-29 MedSci MedSci原创

对危重病人营养摄入的利弊始终存在争议,而其原因可能归结于不同患者营养摄入风险不同所致。本研究的目的是探讨对于危重症患者来说,不同剂量的蛋白质或能量摄入对患者预后的影响,结果将以危重病患者营养风险得分进行评估。

对危重病人营养摄入的利弊始终存在争议,而其原因可能归结于不同患者营养摄入风险不同所致。本研究的目的是探讨对于危重症患者来说,不同剂量的蛋白质或能量摄入对患者预后的影响,结果将以危重病患者营养风险得分进行评估。

采用前瞻性观察队列对来自202个ICU的2853名机械通气大于或等于4天的患者进行研究,其中1605名通气时间大于或等于12天的患者设置为一个研究子组。

使用Logistic回归和Cox比例风险回归分别对低风险组(危重病患者的营养风险< 5)和高风险组(危重症患者营养风险≥5)患者进行分析,评估入ICU后前12天给予营养支持的患者的死亡率和60天内转出ICU的时间。在高风险组患者,摄入更多蛋白质(4天组:比值比,0.93;95% CI,0.89-0.98;P = 0.003和12天组:比值比,0.90;95% CI,0.84-0.96;P = 0.003)和能量(4天组:比值比,0.93;95% CI 0.89-0.97;P<0.001和12天组:比值比,0.88;95% CI,0.83-0.94;P<0.001)后死亡率反而更低。在12天组,营养支持风险和疾病分类、死亡率、蛋白质和能量摄入有极大的关系,而在4天组内此种关联表现并不显着。在高风险组患者,摄入更多蛋白质(4天组:风险比,1.05;95% CI,1.01-1.09;P = 0.01和12天组:风险比,1.09;95% CI,1.03-1.16;P = 0.002)和能量(4天组:风险比,1.05;95% CI,1.01-1.09;P = 0.02和12天组:风险比,1.09;95% CI,1.03-1.16;P = 0.002)后转出ICU时间有下降趋势。在12天组,营养支持风险和存活率、蛋白和能量摄入有极大相关性,然而在4天组表现不显着。

从而我们可以得出结论:在高风险、ICU停留时间久的患者中,更多的营养摄入量可降低患者死亡率,并减少ICU住院时间,但在低风险的患者中这一差别并不显着。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765640, encodeId=66111e6564036, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Aug 18 22:16:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983521, encodeId=cf8f198352123, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 12:16:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809992, encodeId=9dcb18099924f, content=<a href='/topic/show?id=273684289c7' target=_blank style='color:#2F92EE;'>#能量摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84289, encryptionId=273684289c7, topicName=能量摄入)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Jun 06 06:16:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903924, encodeId=7d9d19039248a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Oct 14 18:16:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688965, encodeId=5a70168896585, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Mon Feb 26 13:16:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284005, encodeId=e8131284005d7, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296977, encodeId=affb12969e7b8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526129, encodeId=71ed15261297d, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607750, encodeId=eb49160e750d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765640, encodeId=66111e6564036, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Aug 18 22:16:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983521, encodeId=cf8f198352123, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 12:16:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809992, encodeId=9dcb18099924f, content=<a href='/topic/show?id=273684289c7' target=_blank style='color:#2F92EE;'>#能量摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84289, encryptionId=273684289c7, topicName=能量摄入)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Jun 06 06:16:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903924, encodeId=7d9d19039248a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Oct 14 18:16:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688965, encodeId=5a70168896585, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Mon Feb 26 13:16:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284005, encodeId=e8131284005d7, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296977, encodeId=affb12969e7b8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526129, encodeId=71ed15261297d, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607750, encodeId=eb49160e750d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765640, encodeId=66111e6564036, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Aug 18 22:16:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983521, encodeId=cf8f198352123, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 12:16:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809992, encodeId=9dcb18099924f, content=<a href='/topic/show?id=273684289c7' target=_blank style='color:#2F92EE;'>#能量摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84289, encryptionId=273684289c7, topicName=能量摄入)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Jun 06 06:16:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903924, encodeId=7d9d19039248a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Oct 14 18:16:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688965, encodeId=5a70168896585, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Mon Feb 26 13:16:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284005, encodeId=e8131284005d7, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296977, encodeId=affb12969e7b8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526129, encodeId=71ed15261297d, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607750, encodeId=eb49160e750d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1765640, encodeId=66111e6564036, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Aug 18 22:16:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983521, encodeId=cf8f198352123, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 12:16:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809992, encodeId=9dcb18099924f, content=<a href='/topic/show?id=273684289c7' target=_blank style='color:#2F92EE;'>#能量摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84289, encryptionId=273684289c7, topicName=能量摄入)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Jun 06 06:16:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903924, encodeId=7d9d19039248a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Oct 14 18:16:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688965, encodeId=5a70168896585, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Mon Feb 26 13:16:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284005, encodeId=e8131284005d7, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296977, encodeId=affb12969e7b8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526129, encodeId=71ed15261297d, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607750, encodeId=eb49160e750d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1765640, encodeId=66111e6564036, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Aug 18 22:16:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983521, encodeId=cf8f198352123, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 12:16:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809992, encodeId=9dcb18099924f, content=<a href='/topic/show?id=273684289c7' target=_blank style='color:#2F92EE;'>#能量摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84289, encryptionId=273684289c7, topicName=能量摄入)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Jun 06 06:16:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903924, encodeId=7d9d19039248a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Oct 14 18:16:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688965, encodeId=5a70168896585, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Mon Feb 26 13:16:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284005, encodeId=e8131284005d7, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296977, encodeId=affb12969e7b8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526129, encodeId=71ed15261297d, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607750, encodeId=eb49160e750d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1765640, encodeId=66111e6564036, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Aug 18 22:16:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983521, encodeId=cf8f198352123, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 12:16:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809992, encodeId=9dcb18099924f, content=<a href='/topic/show?id=273684289c7' target=_blank style='color:#2F92EE;'>#能量摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84289, encryptionId=273684289c7, topicName=能量摄入)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Jun 06 06:16:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903924, encodeId=7d9d19039248a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Oct 14 18:16:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688965, encodeId=5a70168896585, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Mon Feb 26 13:16:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284005, encodeId=e8131284005d7, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296977, encodeId=affb12969e7b8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526129, encodeId=71ed15261297d, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607750, encodeId=eb49160e750d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1765640, encodeId=66111e6564036, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Aug 18 22:16:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983521, encodeId=cf8f198352123, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 12:16:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809992, encodeId=9dcb18099924f, content=<a href='/topic/show?id=273684289c7' target=_blank style='color:#2F92EE;'>#能量摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84289, encryptionId=273684289c7, topicName=能量摄入)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Jun 06 06:16:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903924, encodeId=7d9d19039248a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Oct 14 18:16:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688965, encodeId=5a70168896585, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Mon Feb 26 13:16:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284005, encodeId=e8131284005d7, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296977, encodeId=affb12969e7b8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526129, encodeId=71ed15261297d, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607750, encodeId=eb49160e750d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1765640, encodeId=66111e6564036, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Aug 18 22:16:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983521, encodeId=cf8f198352123, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 12:16:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809992, encodeId=9dcb18099924f, content=<a href='/topic/show?id=273684289c7' target=_blank style='color:#2F92EE;'>#能量摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84289, encryptionId=273684289c7, topicName=能量摄入)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Jun 06 06:16:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903924, encodeId=7d9d19039248a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Oct 14 18:16:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688965, encodeId=5a70168896585, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Mon Feb 26 13:16:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284005, encodeId=e8131284005d7, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296977, encodeId=affb12969e7b8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526129, encodeId=71ed15261297d, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607750, encodeId=eb49160e750d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1765640, encodeId=66111e6564036, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Aug 18 22:16:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983521, encodeId=cf8f198352123, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 12:16:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809992, encodeId=9dcb18099924f, content=<a href='/topic/show?id=273684289c7' target=_blank style='color:#2F92EE;'>#能量摄入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84289, encryptionId=273684289c7, topicName=能量摄入)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Jun 06 06:16:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903924, encodeId=7d9d19039248a, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sat Oct 14 18:16:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688965, encodeId=5a70168896585, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Mon Feb 26 13:16:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284005, encodeId=e8131284005d7, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296977, encodeId=affb12969e7b8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526129, encodeId=71ed15261297d, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607750, encodeId=eb49160e750d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 01 04:16:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]

相关资讯

危重症的早期信号及临床特点

随着基层卫生事业的快速发展,基层急救越来越受到关注,基层急救的关键环节是基层医生对危重症的早期识别和及时的处置干预。 急危重症是紧急、濒危的病症,其来势凶、变化快,早期判断与快速处置直接影响到患者的生命安危,因此,全科医师需要练就“火眼金睛”,快速识别急危重症并进行初步处理,与院前急救配合做到安全转运,提高危重病人的抢救成功率。 基层常见急危重症症状包括胸闷、胸痛、呼吸困难、昏

Crit Care:危重患者是否需要补充肠外营养?

营养指南建议不同于肠外营养(PN)的使用,近期的相关观察数据显示,在重症监护病房(ICU)中,早期接受能量/蛋白质的量可以影响患者的死亡率,特别是体重指数(BMI)<25或> 35的营养摄入不足的患者。近期,一项发表在杂志Crit Care上的研究评估了与常规护理(单独使用EN)相比,通过补充PN(SPN)+肠内营养(EN)增加营养供应是否能够改善体重不足和肥胖的ICU患者的60天生存

专题:危重症患者诊疗指南干货,速速围观!

现代诊疗技术的快速发展,高精尖的医疗设备得到了广泛的应用,对从事危重症患者诊疗的医务人员素质提出了更高的要求,危重症的专业性和综合性都比较强,它整合了内科、外科、护理等多个专业的高端技术。危重病人的病情严重随时可能变化,如果抢救及时,护理得当,病人可能转危为安,反之,即可发生生命危险。因此对危重病人的护理是一项非常重要而严肃的工作,是争分夺秒的战斗。梅斯小编整理了危重症患者诊疗相关指南,供大家参考

Crit Care:予以经验性抗生素治疗的更佳时间窗!

适当抗菌药物的早期给药与菌血症患者的预后相关,但早期予以抗生素治疗的最佳时机作为严重细菌感染的复苏策略之一仍不清楚。近期,一项发表在杂志Crit Care上的回顾性队列研究中,研究者们分析了急诊科(ED)中社区起病的菌血症成年人。通过多变量回归分析确定的独立预测因子调整后,评估了予以适当的抗生素(TtAa)施用时间的不同截止值对达到ED后28天死亡率的影响。此项研究结果显示:在2349例患者中,平

危重症的早期信号及临床特点

随着基层卫生事业的快速发展,基层急救越来越受到关注,基层急救的关键环节是基层医生对危重症的早期识别和及时的处置干预。急危重症是紧急、濒危的病症,其来势凶、变化快,早期判断与快速处置直接影响到患者的生命安危,因此,全科医师需要练就“火眼金睛”,快速识别急危重症并进行初步处理,与院前急救配合做到安全转运,提高危重病人的抢救成功率。基层常见急危重症症状包括胸闷、胸痛、呼吸困难、昏迷、抽搐及休克等;猝死的

青年医生朱元方:以生命名义与时间赛跑

时间就是生命。这句话对他来说意义非常。“每一个危重症孕妇的抢救都是一场与时间的赛跑,只有争分夺秒才能赢过死神,挽救新生命,挽救家庭。”作为一名青年妇产科医生,他争分夺秒工作,不放弃任何一位危重症孕产妇的健康;争分夺秒学习,勇攀医学高峰,创造了江西省危重症孕产妇救治的多个第一。在平凡的岗位上,他用自己的实际行动诠释了一个共产党员的优秀品质。他,就是南昌大学一附院妇产科副主任、产科主任、年轻的医学专家

Baidu
map
Baidu
map
Baidu
map